Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Morvan C, Campion L, Blanc-Lapierre A. Supiot S, et al. Among authors: pommier p. Eur Urol. 2021 Oct;80(4):405-414. doi: 10.1016/j.eururo.2021.06.010. Epub 2021 Jul 8. Eur Urol. 2021. PMID: 34247896 Clinical Trial.
Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results.
Bey P, Carrie C, Beckendorf V, Ginestet C, Aletti P, Madelis G, Luporsi E, Pommier P, Cowen D, Gonzague-Casabianca L, Simonian-Sauve M, Maingon P, Naudy S, Lagrange J, Marcie S. Bey P, et al. Among authors: pommier p. Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):513-7. doi: 10.1016/s0360-3016(00)00691-x. Int J Radiat Oncol Biol Phys. 2000. PMID: 10974470
[Standards, Options, and Recommendations for brachytherapy in patients with prostate cancer: efficacy and toxicity].
Pommier P, Villers A, Bataillard A, Brune D, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Daver A, Fontaine E, Guilloneau B, Haillot O, Lagrange JL, Molinié V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnitch D, Ravery V, Richaud P, Rossi D, Soret JY. Pommier P, et al. Cancer Radiother. 2001 Dec;5(6):770-86. doi: 10.1016/s1278-3218(01)00138-x. Cancer Radiother. 2001. PMID: 11797299 French.
[Standards, options, and recommendation for external radiotherapy of prostatic cancer: evaluation of the effect of dosage].
Pommier P, Villers A, Bataillard A, Brune D, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Daver A, Fontaine E, Haillot O, Lagrange JL, Molinié V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnitch D, Ravery V, Richaud P, Rossi D, Soulié M. Pommier P, et al. Cancer Radiother. 2002 Apr;6(2):119-26. doi: 10.1016/s1278-3218(02)00152-x. Cancer Radiother. 2002. PMID: 12035484 French.
[Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: experience of French dose-escalation trials].
Beckendorf V, Bachaud JM, Bey P, Bourdin S, Carrie C, Chapet O, Cowen D, Guérif S, Hay HM, Lagrange JL, Maingon P, Le Prisé E, Pommier P, Simon JM. Beckendorf V, et al. Among authors: pommier p. Cancer Radiother. 2002 Nov;6 Suppl 1:78s-92s. doi: 10.1016/s1278-3218(02)00217-2. Cancer Radiother. 2002. PMID: 12587386 Review. French.
Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001).
Villers A, Pommier P, Bataillard A, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Brune D, Daver A, Fontaine E, Haillot O, Lagrange JL, Molinie V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnich D, Ravery V, Richaud P, Rossi D, Soulie M; FNCLCC; AFU. Villers A, et al. Among authors: pommier p. Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S50-8. doi: 10.1038/sj.bjc.6601084. Br J Cancer. 2003. PMID: 12915903 Free PMC article. No abstract available.
The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P. Beckendorf V, et al. Among authors: pommier p. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1056-65. doi: 10.1016/j.ijrobp.2004.05.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519775 Clinical Trial.
[The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytherapy: feasibility and acute toxicity].
Pommier P, Delannes M, LeFloch O, Bernier V, Baron MH, Thomas L, Malet C, Bonnet J, Louisot P, Aletti P, Goubard O, Chemin A, Chirat F, Lebivic S, Montbarbon X, Bachaud JM, Votron L, Lasbareilles O, Desmettre O, Bringeon G, Gassa F, Peiffert D. Pommier P, et al. Cancer Radiother. 2006 Dec;10(8):559-64. doi: 10.1016/j.canrad.2006.07.008. Epub 2006 Sep 7. Cancer Radiother. 2006. PMID: 16959520 Clinical Trial. French.
195 results